|
Aug 28
|
Adaptimmune to Participate in Two Bank Conferences this September
|
|
Aug 15
|
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago
|
|
Jul 25
|
Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?
|
|
Jun 12
|
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
|
|
May 15
|
Adaptimmune Reports Q1 2024 Financial and Business Updates
|
|
May 15
|
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
|
|
May 1
|
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
|
|
Apr 15
|
Adaptimmune (ADAP) Down on End of Collaboration With Roche
|
|
Apr 12
|
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
|
|
Apr 12
|
Roche, Adaptimmune part ways on cell therapy research
|
|
Mar 27
|
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
|
|
Mar 8
|
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 7
|
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
|
|
Mar 7
|
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
|
|
Jan 17
|
Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
|
|
Jan 16
|
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
|
|
Dec 7
|
Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year
|
|
Dec 6
|
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
|
|
Nov 30
|
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
|